Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

CairnSurgical Breast Cancer Locator (BCL) Post-Market Study

NCT: NCT06461663 · COMPLETED

NCT IDNCT06461663
StatusCOMPLETED
Start Date2022-06-22
Completion2024-04-19

Brief Summary

This interventional, post-market, multicenter clinical investigation is designed to evaluate the performance of a custom-made medical device, "the Breast Cancer Locator (BCL)" in Subjects with non-palpable breast cancer, in Europe.

Frequently Asked Questions

What is CairnSurgical Breast Cancer Locator (BCL) Post-Market Study?

CairnSurgical Breast Cancer Locator (BCL) Post-Market Study is a clinical trial registered under NCT06461663. Current status: COMPLETED.

What is the status of NCT06461663?

The current status of NCT06461663 (CairnSurgical Breast Cancer Locator (BCL) Post-Market Study) is: COMPLETED.

When did CairnSurgical Breast Cancer Locator (BCL) Post-Market Study start?

CairnSurgical Breast Cancer Locator (BCL) Post-Market Study started on 2022-06-22.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑